FHL2 facilitates LUSC growth and therapy resistance through PI3K/AKT/mTOR activation
Abstract Four and a half LIM domain protein 2 (FHL2) plays a key role in tumorigenesis and progression. This study…
Abstract Four and a half LIM domain protein 2 (FHL2) plays a key role in tumorigenesis and progression. This study…
Abstract Drug resistance to a single agent is common in cancer-targeted therapies, and rational drug combinations are a promising approach…
Abstract Cancer constitutes a multifaceted ailment characterized by the dysregulation of numerous genes and pathways. Among these, LIM domain only…
Abstract BACKGROUND: Undifferentiated pleomorphic sarcoma (UPS) is a rare malignant mesenchymal tumor with a poor prognosis. It mainly occurs in…
Abstract Osteoarthritis (OA) is a common degenerative joint disease and is closely associated with chronic, low-grade inflammation. Regulating ferroptosis by…
Abstract Telomerase activation is required for malignant transformation. Recent advances in high‐throughput technologies have enabled the generation of complex datasets,…
Abstract Present study aimed to evaluate the influence of distinct concentration of dietary supplements hemp oil on apparent nutrient digestibility,…
Abstract Cannabinoid receptors typically include type 1 (CB1) and type 2 (CB2), and they have attracted extensive attention in the…
Abstract Identifying driver genes that contribute to cancer progression from numerous passenger genes, although a central goal, is a major…
Abstract A plethora of previous studies have been focused on the role of indoleamine 2,3-dioxygenase 1 (IDO1) in cancer immunity;…